Equities

Vaccinex Inc

VCNX:NAQ

Vaccinex Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.60
  • Today's Change-0.11 / -2.96%
  • Shares traded5.00
  • 1 Year change-70.78%
  • Beta1.0456
Data delayed at least 15 minutes, as of Nov 21 2024 20:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments1.546.398.59
Total Receivables, Net0.960.180
Total Inventory------
Prepaid expenses0.850.910.82
Other current assets, total------
Total current assets3.357.489.41
Property, plant & equipment, net0.280.500.44
Goodwill, net------
Intangibles, net------
Long term investments------
Note receivable - long term------
Other long term assets------
Total assets3.637.989.84
LIABILITIES
Accounts payable2.041.521.06
Accrued expenses1.390.951.12
Notes payable/short-term debt000
Current portion long-term debt/capital leases0.080.070.07
Other current liabilities, total2.41----
Total current liabilities5.922.542.26
Total long term debt0.030.100.18
Total debt0.100.180.25
Deferred income tax------
Minority interest----0
Other liabilities, total00.15--
Total liabilities5.942.782.43
SHAREHOLDERS EQUITY
Common stock0.000.010.00
Additional paid-in capital338325307
Retained earnings (accumulated deficit)(340)(320)(300)
Treasury stock - common(0.01)(0.01)(0.01)
Unrealized gain (loss)------
Other equity, total0.00----
Total equity(2.31)5.197.41
Total liabilities & shareholders' equity3.637.989.84
Total common shares outstanding0.890.240.15
Treasury shares - common primary issue0.0000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.